Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' HERZIG GP' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 52 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Fleming, DR; Wolff, SN; Fay, JW; Brown, RA; Lynch, JP; Bolwell, BJ; Stevens, DA; Goodman, SA; Greer, JP; Stein, RS; Pineiro, LA; Collins, RH; Goldsmith, LJ; Herzig, GP; Herzig, RH
      Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the north American marrow transplant group

      LEUKEMIA & LYMPHOMA
    2. Gale, RP; Park, RE; Dubois, RW; Herzig, GP; Hocking, WG; Horowitz, MM; Keating, A; Kempin, S; Linker, CA; Schiffer, CA; Wiernik, PH; Weisdorf, DJ; Rai, KR
      Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase

      LEUKEMIA RESEARCH
    3. Gale, RP; Park, RE; Dubois, RW; Herzig, GP; Hocking, WG; Horowitz, MM; Keating, A; Kempin, S; Linker, CA; Schiffer, CA; Wiernik, PH; Weisdorf, DJ; Rai, KR
      Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission

      LEUKEMIA RESEARCH
    4. Khatri, VP; Baiocchi, RA; Peng, RQ; Oberkircher, AR; Dolce, JM; Ward, PM; Herzig, GP; Caligiuri, MA
      Endogenous CD8(+) T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder

      JOURNAL OF IMMUNOLOGY
    5. WETZLER M; BERNSTEIN SH; BAUMANN H; FRIES KM; STEWART C; BLUMENSON L; BAER MR; HERZIG GP; BLOOMFIELD CD; SLACK JL
      EXPRESSION AND FUNCTION OF THE MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR-RECEPTOR IN ACUTE MYELOID-LEUKEMIA BLASTS

      Leukemia & lymphoma
    6. TEZCAN H; ZIMMER W; FENSTERMAKER R; HERZIG GP; SCHRIBER J
      SEVERE CEREBELLAR SWELLING AND THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH FK506

      Bone marrow transplantation
    7. GALE RP; PARK RE; DUBOIS RW; HERZIG GP; HOCKING WG; HOROWITZ MM; KEATING A; KEMPIN S; LINKER CA; SCHIFFER CA; WIERNIK PH; WEISDORF DJ; RAI KR
      DELPHI-PANEL ANALYSIS OF APPROPRIATENESS OF HIGH-DOSE THERAPY AND BONE-MARROW TRANSPLANTS IN ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN FIRST REMISSION

      Leukemia research
    8. CALIGIURI MA; STROUT MP; LAWRENCE D; ARTHUR DC; BAER MR; YU F; KNUUTILA S; MROZEK K; OBERKIRCHER AR; MARCUCCI G; DELACHAPELLE A; ELONEN E; BLOCK AW; RAO PN; HERZIG GP; POWELL BL; RUUTU T; SCHIFFER CA; BLOOMFIELD CD
      REARRANGEMENT OF ALL1 (MLL) IN ACUTE MYELOID-LEUKEMIA WITH NORMAL CYTOGENETICS

      Cancer research
    9. SHAH M; JENIS EH; MOOKERJEE BK; SCHRIBER JR; BAER MR; HERZIG GP; WETZLER M
      INTERFERON-ALPHA-ASSOCIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH MASSIVE PROTEINURIA IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA FOLLOWINGHIGH-DOSE CHEMOTHERAPY

      Cancer
    10. BERNSTEIN SH; NADEMANEE AP; VOSE JM; TRICOT G; FAY JW; NEGRIN RS; DIPERSIO J; RONDON G; CHAMPLIN R; BARNETT MJ; CORNETTA K; HERZIG GP; VAUGHAN W; GEILS G; KEATING J; MESSNER H; WOLFF SN; MILLER KB; LINKER C; CAIRO M; HELLMANN S; ASHBY M; STRYKER S; NASH RA
      A MULTICENTER STUDY OF PLATELET RECOVERY AND UTILIZATION IN PATIENTS AFTER MYELOABLATIVE THERAPY AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION

      Blood
    11. BERNSTEIN SH; FAY JP; CHRISTIANSEN NP; PINERO L; SHAH D; STEPHAN M; HERZIG GP
      SEQUENTIAL INTERLEUKIN-3 AND GRANULOCYTE-COLONY-STIMULATING FACTOR PRIOR TO AND FOLLOWING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE - A PHASE I II TRIAL/

      Clinical cancer research
    12. WETZLER M; BAER MR; BERNSTEIN SH; BLUMENSON L; STEWART C; BARCOS M; MROZEK K; BLOCK AMW; HERZIG GP; BLOOMFIELD CD
      EXPRESSION OF C-MPL MESSENGER-RNA, THE RECEPTOR FOR THROMBOPOIETIN, IN ACUTE MYELOID-LEUKEMIA BLASTS IDENTIFIES A GROUP OF PATIENTS WITH POOR RESPONSE TO INTENSIVE CHEMOTHERAPY

      Journal of clinical oncology
    13. BLOOMFIELD CD; HERZIG GP; CALIGIURI MA
      INTRODUCTION - ACUTE-LEUKEMIA - RECENT ADVANCES

      Seminars in oncology
    14. SCHRIBER JR; HERZIG GP
      TRANSPLANTATION-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC-UREMIC SYNDROME

      Seminars in hematology
    15. BLOOMFIELD CD; HERZIG GP; PETERSON BA; WOLFF SN
      LONG-TERM SURVIVAL OF PATIENTS WITH ACUTE MYELOID-LEUKEMIA - UPDATED RESULTS FROM 2 TRIALS EVALUATING POSTINDUCTION CHEMOTHERAPY

      Cancer
    16. BERNSTEIN SH; EAVES CJ; HERZIG R; FAY J; LYNCH J; PHILLIPS GL; CHRISTIANSEN N; REECE D; ERICSON S; STEPHAN M; KOVALSKY M; HAWKINS K; RASMUSSEN H; DEVOS A; HERZIG GP
      A RANDOMIZED PHASE-II STUDY OF BB-10010 - A VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA FOR PATIENTS RECEIVING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR MALIGNANT-LYMPHOMA AND BREAST-CANCER

      British Journal of Haematology
    17. BERNSTEIN SH; EAVES CJ; HERZIG R; FAY J; LYNCH J; PHILLIPS GL; CHRISTIANSEN N; REECE D; ERICSON S; STEPHAN M; KOVALSKY M; HAWKINS K; RASMUSSEN H; DEVOS A; HERZIG GP
      A RANDOMIZED PHASE-II STUDY OF BB-10010 - A VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA (MIP-1-ALPHA) FOR PATIENTS RECEIVING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR MALIGNANT-LYMPHOMA AND BREAST-CANCER

      Blood
    18. BROWN RA; WOLFF SN; FAY JW; PINEIRO L; COLLINS RH; LYNCH JP; STEVENS D; GREER J; HERZIG RH; HERZIG GP
      HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION WITHALLOGENEIC BONE-MARROW TRANSPLANTATION FOR RESISTANT ACUTE MYELOID-LEUKEMIA - A STUDY BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP

      Leukemia & lymphoma
    19. BERNSTEIN SH; CHRISTIANSEN NP; FAY JP; BROWN R; HERZIG R; FRANKEL S; BLUMENSON L; HERZIG GP
      GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) PRIMING OF HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE - A PILOT TRIAL

      Experimental hematology
    20. LAUGHLIN MJ; CHRISTIANSEN NP; HERZIG GP; BLUMENSON L; BONNEY D; STEWART CC
      CD34 PROGENITOR-CELL SUBSET ANALYSES IN NORMAL HUMAN BONE-MARROW AND MARROW HARVESTED AFTER INTERMEDIATE-DOSE CHEMOTHERAPY

      Cytometry
    21. HERZIG RH; LYNCH J; CHRISTIANSEN NP; FAY JW; DAVIS MP; HERZIG GP
      DOSE-INTENSIVE CHEMOTHERAPY WITH ETOPOSIDE-CYCLOPHOSPHAMIDE FOR ADVANCED BREAST-CANCER

      Seminars in oncology
    22. CALIGIURI MA; STROUT MP; SCHICHMAN SA; MROZEK K; ARTHUR DC; HERZIG GP; BAER MR; SCHIFFER CA; HEINONEN K; KNUUTILA S; NOUSIAINEN T; RUUTU T; BLOCK AW; SCHULMAN P; PEDERSENBJERGAARD J; CROCE CM; BLOOMFIELD CD
      PARTIAL TANDEM DUPLICATION OF ALL1 AS A RECURRENT MOLECULAR DEFECT INACUTE MYELOID-LEUKEMIA WITH TRISOMY-11

      Cancer research
    23. JURLANDER J; CALIGIURI MA; RUUTU T; BAER MR; STROUT MP; OBERKIRCHER AR; HOFFMANN L; BALL ED; FREILAHR DA; CHRISTIANSEN NP; BLOCK AW; KNUUTILA S; HERZIG GP; BLOOMFIELD CD
      PERSISTENCE OF THE AML1 ETO FUSION TRANSCRIPT IN PATIENTS TREATED WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR T(8-21) LEUKEMIA/

      Blood
    24. SCHRIBER JR; BAER MR; CHRISTIANSEN NP; MCCARTHY PL; SLACK JL; TEZCAN H; WETZLER M; HERZIG GP
      MURINE MONOCLONAL-ANTIBODY DIRECTED AGAINST CD3 (OKT3) IS AN EFFECTIVE TREATMENT FOR MODERATE (GRADE-II) BUT NOT FOR SEVERE (GRADE-III OR GRADE-IV) STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE (GVHD)

      Blood
    25. SCHRIBER JR; MOOKERJEE BK; BAER MR; CHRISTIANSEN NP; MCCARTHY PL; SLACK JL; TEZCAN H; WETZLER M; HERZIG GP
      EFFICACY OF HEMODIALYSIS (HD) AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)

      Blood
    26. SCHRIBER JR; MILK BJ; BAER MR; CHRISTIANSEN NP; MCCARTHY PL; SLACK JL; TEZCAN H; WETZLER M; HERZIG GP
      A RANDOMIZED PHASE-II TRIAL COMPARING HEPARIN (HEP)+ -PROSTAGLANDIN-E1 (PG) TO PREVENT HEPATOTOXICTY (HT) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) - PRELIMINARY-RESULTS/

      Blood
    27. WETZLER M; BAER MR; BERNSTEIN SH; BLUMENSON L; STEWART C; BARCOS M; MROZEK K; BLOCK AMW; HERZIG GP; BLOOMFIELD CD
      EXPRESSION OF MESSENGER-RNA ENCODING C-MPL, THE RECEPTOR FOR THROMBOPOIETIN, IN ACUTE MYELOID-LEUKEMIA (AML) BLASTS IDENTIFIES A GROUP OF PATIENTS (PTS) WITH POOR OUTCOME TO INTENSIVE CHEMOTHERAPY

      Blood
    28. BAER MR; BERNSTEIN SH; BRUNETTO VL; HEINONEN K; MROZEK K; SWANN VL; MINDERMAN H; BLOCK AW; PIXLEY LA; CHRISTIANSEN NP; FAY JW; BARCOS M; RUSTUM Y; HERZIG GP; BLOOMFIELD CD
      BIOLOGICAL EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH UNTREATED ACUTE MYELOID-LEUKEMIA

      Blood
    29. OBERKIRCHER AR; STROUT MP; HERZIG GP; FRITZ PD; CALIGIURI MA
      DESCRIPTION OF AN EFFICIENT AND HIGHLY INFORMATIVE METHOD FOR THE EVALUATION OF HEMATOPOIETIC CHIMERISM FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION

      Bone marrow transplantation
    30. BERNSTEIN SH; BAER MR; STEWART C; SLACK JL; LAWRENCE D; HERZIG GP; BLOOMFIELD CD; WETZIER M
      EXPRESSION OF THE C-MPL RECEPTOR ON LEUKEMIC BLASTS FROM PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)

      Blood
    31. BERNSTEIN SH; BAER MR; LAWRENCE D; HERZIG GP; BLOOMFIELD CD; WETZLER M
      SERIAL DETERMINATION OF THROMBOPOIETIN (TPO), IL-3, IL-6, IL-11 AND LEUKEMIA INHIBITORY FACTOR (LIF) LEVELS IN PATIENTS UNDERGOING CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA (AML)

      Blood
    32. NANTEL SH; BERNSTEIN SH; STEVENS DA; FAY JW; HERZIG RH; PHILLIPS GL; HERZIG GP; GARRISON L
      DOSE-ESCALATION STUDY OF PIXY321 POST AUTOLOGOUS BONE-MARROW TRANSPLANT (BMT) FOR HODGKINS-DISEASE (HD) OR NON-HODGKINS-LYMPHOMA (NHL)

      Blood
    33. STROUT MP; CALIGIURI MA; SCHICHMAN SA; MROZEK K; HERZIG GP; ARTHUR DC; HEINONEN K; KNUUTILA S; NOUSIAINEN T; RUUTU T; BLOCK AW; CROCE CM; BLOOMFIELD CD
      THE PARTIAL TANDEM DUPLICATION OF ALL1 IS A RECURRENT NOVEL MOLECULARDEFECT IN ACUTE MYELOID-LEUKEMIA (AML) WITH TRISOMY-11

      Blood
    34. SLACK JL; BAER MR; BERNSTEIN SH; STEWART C; LAWRENCE D; HERZIG GP; BLOOMFIELD CD; WETZIER M
      ACUTE MYELOID-LEUKEMIA (AML) BLAST CELL-PROLIFERATION AND DIFFERENTIATION IN RESPONSE TO MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (MGDF)

      Blood
    35. JURLANDER J; CALIGIURI MA; STROUT MP; BALL ED; FREILAHR DA; HOFFMANN L; OBERKIRCHER AR; CHRISTIANSEN NP; BLOCK AW; HERZIG GP; BLOOMFIELD CD
      PERSISTENCE OF THE T(8-21) FUSION TRANSCRIPT FOLLOWING ALLOGENEIC (ALLO) BONE-MARROW TRANSPLANTATION (BMT) FOR ACUTE MYELOID-LEUKEMIA (AML)

      Blood
    36. STONE RM; PIRO ID; SAVEN A; BERG DT; BRYAN WJ; FAY JW; HERZIG GP; HERZIG RH; SHIELDS AF; COLEMAN BS; LEE EJ
      A PHASE-I NOVEL ALKYLATING AGENT (AA), ADOZELESIN PATIENTS (PTS) WITHREFRACTORY HEMATOLOGIC MALIGNANCIES (HM)

      Blood
    37. GALE RP; HERZIG GP; HOCKING WG; HOROWITZ MM; KEATING A; KEMPIN S; LINKER CA; PARK ER; RAI K; SCHIFFER CA; WEISDORF DJ; DUBOIS R; WIERNIK PH
      ALL IN 1ST REMISSION - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS

      Blood
    38. GALE RP; HERZIG GP; HOCKING WG; HOROWITZ MM; KEATING A; KEMPIN S; LINKER CA; PARK ER; RAI K; SCHIFFER CA; WEISDORF DJ; DUBOIS R; WIERNIK PH
      AML IN 1ST REMISSION - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS

      Blood
    39. GALE RP; HERZIG GP; HOCKING WG; HOROWITZ MM; KEATING A; KEMPIN S; LINKER CA; PARK ER; RAI K; SCHIFFER CA; WEISDORF DJ; DUBOIS R; WIERNIK PH
      CML IN CHRONIC PHASE - RAND-DELPHI ANALYSIS OF APPROPRIATENESS OF BONE-MARROW TRANSPLANTS

      Blood
    40. BROWN RA; WOLFF SN; FAY JW; PINEIRO L; COLLINS RH; LYNCH JP; STEVENS D; GREER J; HERZIG RH; HERZIG GP
      HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICANMARROW TRANSPLANT GROUP

      Blood
    41. CALIGIURI MA; SCHICHMAN SA; STROUT MP; MROZEK K; BAER MR; FRANKEL SR; BARCOS M; HERZIG GP; CROCE CM; BLOOMFIELD CD
      MOLECULAR REARRANGEMENT OF THE ALL-1 GENE IN ACUTE MYELOID-LEUKEMIA WITHOUT CYTOGENETIC EVIDENCE OF 11Q23 CHROMOSOMAL TRANSLOCATIONS

      Cancer research
    42. BROWN RA; WOLFF S; FAY J; PINEIRO L; GREER J; LYNCH J; COLLINS R; STEVENS D; HERZIG R; HERZIG GP
      HIGH-DOSE CYTOSINE-ARABINOSIDE (HDAC) DAUNORUBICIN (DNR) INDUCTION FOLLOWED BY HIGH-DOSE ETOPOSIDE (VP) CYCLOPHOSPHAMIDE (CY) CONSOLIDATIONFOR PATIENTS (PTS) WITH AML

      Blood
    43. BAER MR; LO CH; MEANS J; SALZMAN G; FRANKEL SR; LAWRENCE D; MOORE JO; HERZIG GP; SCHIFFER CA; BLOOMFIELD CD; STEWART CC
      MULTIPARAMETER FLOW-CYTOMETRY (MFC) MONITORS RESIDUAL DISEASE (RD) DURING COMPLETE REMISSION (CR) OF ACUTE MYELOID-LEUKEMIA (AML)

      Blood
    44. BAER MR; STEWART CC; LAWRENCE D; ARTHUR DC; DAVEY FR; MROZEK K; CALIGIURI MA; HERZIG GP; SCHIFFER CA; BLOOMFIELD CD
      ACUTE MYELOID-LEUKEMIA WITH 11Q23 CHROMOSOME ALL-1 GENE REARRANGEMENTS DOES NOT EXHIBIT MIXED LINEAGE ANTIGEN EXPRESSION BY MULTIPARAMETER FLOW-CYTOMETRY

      Blood
    45. BAER MR; CHRISTIANSEN NP; FRANKEL SR; BRUNETTO VL; MROZEK K; BLOOMFIELD CD; HERZIG GP
      HIGH-DOSE CYTARABINE, IDARUBICIN, AND GRANULOCYTE-COLONY-STIMULATING FACTOR REMISSION INDUCTION THERAPY FOR PREVIOUSLY UNTREATED DE-NOVO AND SECONDARY ADULT ACUTE MYELOID-LEUKEMIA

      Seminars in oncology
    46. BROWN RA; WOLFF S; FAY J; PINEIRO L; GREEN J; LYNCH J; COLLINS R; STEVENS D; HERZIG R; HERZIG GP
      HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, TOTAL-BODY IRRADIATION (VP CY/TBI) AND ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) FOR PATIENTS WITH RESISTANT ACUTE MYELOID-LEUKEMIA (AML) - A PHASE-I-II TRIAL BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP/

      Blood
    47. LAUGHLIN M; LOFTUS J; HERZIG GP; CALIGIURI T; CALIGIURI M
      NATURAL-KILLER (NK) CELL-ACTIVITY FOLLOWING DOSE-INTENSIVE CHEMOTHERAPY (CT)

      Blood
    48. FAY JW; FELSER J; LAZARUS HM; HERZIG R; SAEZ R; STEVENS D; COLLINS RH; PINERO L; COOPER B; HERZIG GP; CAMPION M; DICESARE J; BERNSTEIN SH
      SEQUENTIAL ADMINISTRATION OF INTERLEUKIN-3 (RHIL-3) AND RHGM-CSF FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION - AN UPDATE OF THE PHASE-I II TRIAL/

      Blood
    49. BAER MR; BERNSTEIN SH; BRUNETTO VL; MINDERMAN H; RUSTUM Y; BLOCK AW; MROZEK K; BLOOMFIELD CD; HERZIG GP
      IN-VIVO RECOMBINANT HUMAN G-CSF PRIMING IN PREVIOUSLY UNTREATED ACUTEMYELOID-LEUKEMIA

      Blood
    50. OBERKIRCHER AR; STROUT MP; HERZIG GP; CALIGIURI MA
      PCR AMPLIFICATION OF MINISATELLITES FOR THE EVALUATION OF HEMATOPOIETIC CHIMERISM FOLLOWING ALLOGENEIC BMT - DESCRIPTION OF AN EFFICIENT AND HIGHLY INFORMATIVE METHOD

      Blood
    51. LAUGHLIN M; CHRISTIANSEN NP; STEWART CC; NETTLETON A; BONNEY D; HERZIG GP
      MEASUREMENT OF LINEAGE-COMMITTED CD34-MARROW PROGENITORS IN ALLOGENEIC TRANSPLANTATION( BONE)

      Blood
    52. WOLFF SN; FAY JW; HERZIG RH; GREER JP; DUMMER S; BROWN RA; COLLINS RH; STEVENS DA; HERZIG GP
      HIGH-DOSE WEEKLY INTRAVENOUS IMMUNOGLOBULIN TO PREVENT INFECTIONS IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION OR SEVERE MYELOSUPPRESSIVE THERAPY - A STUDY OF THE AMERICAN-BONE-MARROW-TRANSPLANT-GROUP

      Annals of internal medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 06:00:57